Supporting data for “Gut Microbiome Regulates Immunotherapy Response through Systemic Immune Environment in Patients with Hepatocellular Carcinoma”

This dataset was originated from the thesis entitled "Gut Microbiome Regulates Immunotherapy Response through Systemic Immune Environment in Patients with Hepatocellular Carcinoma", including metagenomic sequencing and flow cytometry data. Immune checkpoint inhibitors (ICIs) have emerged as the pillars of anticancer treatment for hepatocellular carcinoma (HCC). Nevertheless, only few patients could benefit from ICIs. Most efforts have been directed toward identifying biomarkers of ICIs response more than 6 months, while biomarkers to predict long-term benefits are scarce. Gut microbiota is related with the incidence, progression of several cancer types. There is also a crosstalk between gut microbiota and immune systems, which has the potential of predicting immunotherapy response. In this study, we performed an integrative analysis of gut commensal bacteria and systemic immune, to assess their prospective role on outcomes of HCC patients treated with immunotherapy and establish their causal links.

本数据集源自题为《肝细胞癌患者肠道菌群通过全身免疫环境调控免疫治疗应答》的研究论文，包含宏基因组测序（metagenomic sequencing）与流式细胞术（flow cytometry）数据。免疫检查点抑制剂（immune checkpoint inhibitors, ICIs）已成为肝细胞癌（hepatocellular carcinoma, HCC）抗肿瘤治疗的核心支柱疗法。然而，仅少数患者能从ICIs治疗中获益。当前多数研究致力于识别可预测免疫检查点抑制剂6个月以上应答的生物标志物，但可预测长期治疗获益的生物标志物仍较为匮乏。肠道菌群与多种癌症的发生、进展密切相关，且肠道菌群与免疫系统之间存在交互串扰，具备预测免疫治疗应答的潜力。本研究对肠道共生菌与全身免疫开展整合分析，以评估其在接受免疫治疗的肝细胞癌患者预后中的潜在作用，并明确二者间的因果关联。